News

Dr. Melissa Yuan discusses the impact of weight and postmenstrual age on foveal maturation in preterm infants, highlighting critical insights for neonatal care.

Investigators reveal severe ocular injuries from high-pressure water jets used in riots, highlighting risks and the need for preventive measures.

Dr. J. Peter Campbell discusses the technologies shaping retinopathy of prematurity detection, clinical integration, and global implementation.

Kiora Pharmaceuticals advances ocular therapies with new patents for KIO-104, targeting retinal inflammation and enhancing treatment options.

The company noted that this approval marks Celltrion's first Health Canada-approved biologic product in ophthalmology.

Discover in this case how Dr. Tanit Wongwibulsin digitized his cataract surgery, enhancing efficiency and ensuring precise data management. This transformation allowed him to save time per procedure, nearly doubling his surgical volume. Additionally, the adoption of the digital workflow led to a substantial increase in cases involving premium IOLs.

Discover cutting-edge retinal technologies and treatments at the FLORetina International Congress in Florence, featuring top exhibitors and expert presentations.

Phakic IOLs deliver a “wow” factor to refractive surgery patients, says Matteo Piovella, MD

The two meetings will be held concurrently from December 4-7 in Florence, Italy

Expanding accessibility in ophthalmic training does not require expensive, intricate programming, but reasonable, simple actions from senior clinicians

Clinicians must assume responsibility for this common surgical concern

AnnMarie Hipsley, DPT, PhD, explores innovative approaches in ocular biomechanics, shifting focus from lenses to holistic treatments for presbyopia, enhancing vision care.

Inder Paul Singh, MD, discusses groundbreaking findings on the iDose implant's efficacy and safety in glaucoma management during cataract surgery.

David A. Eichenbaum, MD, FASRS, discusses findings on UBX-1325 for diabetic macular edema, highlighting a shift towards personalized, multi-mechanism therapies.

Chhablani discusses key findings on retinal vasculitis from the FAERS database, highlighting trends and safety in intravitreal treatments.

Kenneth C. Fan, MD, discusses promising visual improvements from MCO-010 therapy for Stargardt disease at AAO 2025, highlighting future treatment potential.

Stephen Tsang, MD, PhD, reviews promising optogenetic therapy results for retinitis pigmentosa and Stargardt disease, enhancing vision and mobility for patients.

James Chelnis explores innovative energy-based technologies in aesthetic facial surgery, emphasizing safety, personalized treatments, and future advancements in patient care.

Karolinne M. Rocha, MD, PhD, shares advancements in vision correction and patient satisfaction at the AAO 2025 meeting.

The EXTEND trial provided 5-year follow-up for 10 patients with advanced retinitis pigmentosa, who had previously received MCO-010 during a phase 1/2a trial

Data suggests that EYP-1901 can reduce the number of injections and treatment burden for patients

Adverum Biotechnologies is known for its therapeutic candidate Ixo-vec, in development for the treatment of wet age-related macular degeneration (AMD)